{
  "id": "601c42ad1cb411341a00001b",
  "type": "factoid",
  "question": "Brensocatib was tested for treatment of which disease?",
  "ideal_answer": "Brensocatib was tested for bronchiectasis. Brensocatib in patients with bronchiectasis was associated with improvements in bronchiectasis clinical outcomes.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32897034"
  ],
  "snippets": [
    {
      "text": "Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32897034",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "METHODS: In a phase 2, randomized, double-blind, placebo-controlled trial, we randomly assigned, in a 1:1:1 ratio, patients with bronchiectasis who had had at least two exacerbations in the previous year to receive placebo, 10 mg of brensocatib, or 25 mg of brensocatib once daily for 24 weeks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32897034",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this 24-week trial, reduction of neutrophil serine protease activity with brensocatib in patients with bronchiectasis was associated with improvements in bronchiectasis clinical outcomes. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32897034",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32897034",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "this 24-week trial, reduction of neutrophil serine protease activity with brensocatib in patients with bronchiectasis was associated with improvements in bronchiectasis clinical outcomes. (F",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32897034",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "cerbations. Brensocatib (INS1007) is an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), an enzyme responsible for the activation of neutrophil serine proteases.METHODS: In a phase 2, randomized, double-blind, placebo-controlled trial, we randomly assigned, in a 1:1:1 ratio, patients with bronchiectasis who had had at least two exacerbations in the previous year to receive placebo, 10 mg of brensocatib, or 25 mg of brensocatib onc",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32897034",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "the 24-week treatment period. The incidence of dental and skin adverse events of special interest was higher with the 10-mg and 25-mg brensocatib doses, respectively, than with placebo.CONCLUSIONS: In this 24-week trial, reduction of neutrophil serine protease activity with brensocatib in patients with bronchiectasis was associated with improv",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32897034",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "bronchiectasis"
}